FLuc Reporter Cell Line - NCI-H660

NCI-H660 is a rare and highly aggressive human prostate cancer cell line, originally derived from a lymph node metastasis of an extrapulmonary small cell carcinoma originating in the prostate gland of a 63-year-old male patient. Exhibiting mixed growth properties—growing primarily as floating aggregates of round cells with some loosely attached cells—NCI-H660 serves as a premier model for neuroendocrine prostate cancer (NEPC). It is distinctively notable for its androgen receptor (AR) negativity, androgen-independent growth, and the presence of a homozygous intronic deletion resulting in the classic TMPRSS2-ERG gene fusion. The FLuc Reporter Cell Line - NCI-H660 advances this critical oncological model through the stable genetic integration of the firefly luciferase (FLuc) gene into the cellular genome. This precise engineering enables the cells to constitutively express the luciferase enzyme, producing a robust and easily quantifiable bioluminescent signal upon exposure to the substrate D-luciferin. Crucially, the genetic modification preserves the essential biological properties, unique growth dynamics, and complex molecular signature of the parental NEPC line, ensuring that experimental models remain biologically authentic and clinically relevant.

The functional integration of the FLuc reporter makes the NCI-H660 cell line an indispensable asset for both in vitro laboratory analytics and advanced preclinical animal modeling. In standard benchtop environments, the steady bioluminescent output provides a highly sensitive, continuous metric for quantifying cell proliferation, monitoring viability, and conducting high-throughput screening of novel chemotherapeutics or targeted treatments—such as Aurora kinase inhibitors—aimed at aggressive NEPC. The primary advantage of this reporter line, however, is realized in complex in vivo research. Because neuroendocrine prostate cancer typically represents a lethal, hormone-therapy-resistant stage of the disease that lacks standard prostate-specific antigen (PSA) expression, dynamically tracking its progression is critical. When implanted into immunodeficient mice to establish localized or metastatic cell line-derived xenograft (CDX) models, the continuous light emission facilitates highly sensitive, non-invasive bioluminescence imaging (BLI).